Ubs Group Ag C4 Therapeutics, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 61,650 shares of CCCC stock, worth $152,275. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,650

Previous 572,026 89.22%

Holding current value

$152,275

Previous $817,000 83.35%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$1.47 - $3.57 $750,252 - $1.82 Million	-510,376 Reduced 89.22%	61,650 $136,000
Q2 2025 Aug 14, 2025	SELL	$1.1 - $1.74 $330,818 - $523,294	-300,744 Reduced 34.46%	572,026 $817,000
Q1 2025 May 13, 2025	BUY	$1.6 - $4.09 $183,868 - $470,014	114,918 Added 15.16%	872,770 $1.4 Million
Q4 2024 Feb 14, 2025	BUY	$3.6 - $7.0 $1.53 Million - $2.97 Million	423,771 Added 126.85%	757,852 $2.73 Million
Q3 2024 Nov 14, 2024	SELL	$4.43 - $7.38 $310,263 - $516,873	-70,037 Reduced 17.33%	334,081 $1.9 Million

Q2 2024 Aug 13, 2024	SELL	$4.05 - $8.1 $1.18 Million - $2.37 Million	-292,559 Reduced 41.99%	404,118 $1.87 Million
Q1 2024 May 13, 2024	BUY	$5.3 - $11.0 $2.22 Million - $4.6 Million	418,302 Added 150.27%	696,677 $5.69 Million
Q4 2023 Feb 09, 2024	SELL	$1.18 - $6.03 $51,016 - $260,701	-43,234 Reduced 13.44%	278,375 $1.57 Million
Q3 2023 Nov 09, 2023	BUY	$1.81 - $3.89 $93,770 - $201,529	51,807 Added 19.2%	321,609 $598,000
Q2 2023 Aug 11, 2023	BUY	$2.75 - $3.77 $294,668 - $403,963	107,152 Added 65.88%	269,802 $741,000
Q1 2023 May 12, 2023	SELL	$3.1 - $9.02 $333,467 - $970,281	-107,570 Reduced 39.81%	162,650 $510,000
Q4 2022 Feb 08, 2023	SELL	$5.42 - $10.24 $253,791 - $479,488	-46,825 Reduced 14.77%	270,220 $1.59 Million
Q3 2022 Nov 10, 2022	SELL	$8.03 - $12.77 $242,032 - $384,900	-30,141 Reduced 8.68%	317,045 $2.78 Million
Q2 2022 Aug 10, 2022	BUY	$5.06 - $26.46 $89,096 - $465,907	17,608 Added 5.34%	347,186 $2.62 Million
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $264,267 - $439,300	-13,220 Reduced 3.86%	329,578 $8 Million
Q4 2021 Feb 14, 2022	SELL	$29.39 - $46.86 $2.19 Million - $3.49 Million	-74,555 Reduced 17.86%	342,798 $11 Million
Q3 2021 Nov 15, 2021	BUY	$35.91 - $50.5 $573,841 - $806,990	15,980 Added 3.98%	417,353 $18.6 Million
Q2 2021 Aug 13, 2021	BUY	$30.39 - $42.18 $4.22 Million - $5.86 Million	138,935 Added 52.94%	401,373 $15.2 Million
Q1 2021 May 12, 2021	BUY	$31.96 - $46.5 $5.17 Million - $7.52 Million	161,722 Added 160.57%	262,438 $9.71 Million
Q4 2020 Feb 11, 2021	BUY	$22.8 - $37.05 $2.3 Million - $3.73 Million	100,716 New	100,716 $3.34 Million

Others Institutions Holding CCCC

# of Institutions

109

Shares Held

55.4M

Call Options Held

329K

Put Options Held

186K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $121M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account